Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, L.R., Spain; Division of Nuclear Medicine, Department of Anaesthesiology, Oncology and Radiology, Faculty of Medical Sciences, Campinas University, Campinas, Brazil
Auto-generated profile, based on publicly available information
Ludmila Santiago Almeida
Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, L.R., Spain; Division of Nuclear Medicine, Department of Anaesthesiology, Oncology and Radiology, Faculty of Medical Sciences, Campinas University, Campinas, Brazil
[18F]FDG PET/CT is the most widely used PET radiopharmaceutical in oncology, but it is not exempt of diagnostic limitations. FAPI have emerged as a great tool in the management of several different solid tumours in which [18F]FDG is not able to provide enough information. The aim of this work was to evaluate the available evidence on diagnostic and therapeutic applications of PET/CT with FAPI radiopharmaceuticals. We underwent a non-systematic review focusing in the utility of FAPI radiopharmaceuticals in PET/CT diagnosis and in the treatment of several malignancies. FAPI radiopharmaceuticals present characteristics that can potentially overcome some known diagnostic limitations of [18F]FDG. FAPI radiopharmaceuticals present a high target-to-background ratio (TBR) in many solid tumours such as oesophageal cancer, gastric cancer, pancreatic cancer, hepatic cancer, colorectal cancer, breast cancer, ovarian, cervical cancer, and head and neck cancer. Available evidence suggests the high TBR improves sensitivity and specificity compared to [18F]FDG, especially for the detection of lymphadenopathies and peritoneal metastases, and may improve patient management and radiation treatment planning. Moreover, it is important to underline the potential theranostic application of FAPI radiopharmaceuticals.
To perform a head-to-head comparison of the uptake pattern of F-18 fluorodeoxyglucose in positron emission computed tomography (FDG PET/CT) in radioiodine refractory thyroid carcinomas (RAIR) in the same patient under elevated TSH levels (eTSH) and suppressed TSH levels (sTSH). FDG PET/CT studies were performed under two conditions: levothyroxine intake (sTSH) and 30 days after hormonal withdrawal (eTSH). SUVmax values and the number of lesions detected (local recurrence and metastases in cervical and distant lymph nodes, lungs and bone) where blindly evaluated. Blood serum TSH and Tg levels were obtained prior to both studies. FDG PET/CT imaging, neck ultrasound, biopsy and follow-up were considered the reference standard. Fifteen patients performed both eTSH and sTSH FDG PET/CT studies. Both were positive for metastases in 80% of the patients. eTSH FDG PET/CT studies did not reveal increased uptake (p = 0.0640) and did not demonstrate a higher number of lesions (p = 0.320) when compared to sTSH FDG PET/CT studies. There was no change in the clinical management of these patients. eTSH FDG PET/CT in patients with RAIR did not show more metastases in comparison to sTSH FDG PET/CT and there was no impact in clinical management of patients. Elevating TSH levels (whether by hormonal withdrawal or recombinant TSH) in patients being submitted to FDG PET/CT may not be necessary.
BACKGROUND TENIS syndrome (Thyroglobulin-Elevated Negative Iodine Scintigraphy) in differentiated thyroid carcinoma is characterized by reduced expression of sodium-iodine symporter, rising serum thyroglobulin levels (Tg), and negative whole-body [131I]Iodine scans. In such patients, somatostatin receptor imaging with [68Ga]Ga-DOTATATE PET/CT (SSR PET/CT) and [18F]F-FDG PET/CT (FDG PET/CT) can identify metastases. To compare the uptake pattern of SSR PET/CT and FDG PET/CT in papillary thyroid carcinoma (PTC) patients with TENIS Syndrome under two conditions: elevated (eTSH) and suppressed (sTSH) TSH serum levels. Based on imaging findings in these patients, we intend to identify potential candidates for peptide receptor radionuclide therapy (PRRNT). Fifteen patients with PTC and TENIS Syndrome were prospectively enrolled. All patients underwent both SSR PET/CT and FDG PET/CT with sTSH and eTSH. Images were blindly evaluated for differences in SUVmax values and lesion detectability. The reference standard consisted of neck ultrasound, CT, MRI, PET/CT, biopsy, and follow-up. Three patients were selected for PRRNT due to lesion uptake similar or higher than the liver. RESULTS On a per-patient and on a per-lesion based analysis, sTSH SSR PET/CT detected a greater number of cervical and distant LNs (both p = 0.0253 on per-patient and p = 0.0176 and p = 0.0391 on per-lesion, respectively) when compared to sTSH FDG PET/CT. Likewise, eTSH SSR PET/CT detected a greater number of patients with local recurrences (p = 0.0455) and distant LN metastases (p = 0.0143) and in a per-lesion based analysis greater number of cervical and distant LNs (p = 0.0337 and p = 0.0039, respectively) when compared to eTSH FDG PET/CT. No differences were found for lung and bone metastases. One of three patients submitted to 3 cycles of PRRNT presented with a visual partial response, a 20% reduction in quantitative analyses and stable disease regarding Tg and TgAb levels. CONCLUSIONS In patients with PTC and TENIS Syndrome, SSR PET/CT detected a greater number of loco-regional and distant LN metastases than FDG PET/CT with both sTSH and eTSH. One of 3 patients submitted to PRRNT presented a partial response to treatment. Our findings may impact in patient restaging, management and theranostics strategies with radiolabeled somatostatin analogs.